Bocchetti M, Misso G, Zappavigna S, Scrima M, Caraglia M, Pentimalli F, Cossu AM. Advancing prognostic understanding in hepatocellular carcinoma through the integration of genomic instability and lncRNA signatures: GILncSig model. World J Gastrointest Surg 2024; 16(9): 2774-2777 [PMID: 39351545 DOI: 10.4240/wjgs.v16.i9.2774]
Corresponding Author of This Article
Alessia Maria Cossu, PhD, Academic Research, Assistant Professor, Research Scientist, Senior Researcher, Department of Precision Medicine, University of Campania “Luigi Vanvitelli”, Via De Crecchio 7, Naples 80138, Italy.alessiamaria.cossu@unicampania.it
Research Domain of This Article
Oncology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Surg. Sep 27, 2024; 16(9): 2774-2777 Published online Sep 27, 2024. doi: 10.4240/wjgs.v16.i9.2774
Advancing prognostic understanding in hepatocellular carcinoma through the integration of genomic instability and lncRNA signatures: GILncSig model
Marco Bocchetti, Gabriella Misso, Silvia Zappavigna, Marianna Scrima, Michele Caraglia, Francesca Pentimalli, Alessia Maria Cossu
Marco Bocchetti, Gabriella Misso, Silvia Zappavigna, Michele Caraglia, Alessia Maria Cossu, Department of Precision Medicine, University of Campania “Luigi Vanvitelli”, Naples 80138, Italy
Marco Bocchetti, Marianna Scrima, Alessia Maria Cossu, Department of Molecular and Precision Oncology, Biogem Scarl, Institute of Genetic Research, Ariano Irpino 83031, Italy
Francesca Pentimalli, Department of Medicine and Surgery, LUM University Giuseppe De Gennaro, Casamassima 70010, Italy
Co-corresponding authors: Francesca Pentimalli and Alessia Maria Cossu.
Author contributions: Bocchetti M and Cossu AM conceptualized, wrote and edited the manuscript; Misso G, Zappavigna S, Scrima M and Caraglia M contributed to the editing of the manuscript; Pentimalli F supervised and edited the manuscript. All authors read and approved the final manuscript
Conflict-of-interest statement: The authors declare that they have no conflicts of interests.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Alessia Maria Cossu, PhD, Academic Research, Assistant Professor, Research Scientist, Senior Researcher, Department of Precision Medicine, University of Campania “Luigi Vanvitelli”, Via De Crecchio 7, Naples 80138, Italy.alessiamaria.cossu@unicampania.it
Received: April 5, 2024 Revised: June 17, 2024 Accepted: June 25, 2024 Published online: September 27, 2024 Processing time: 165 Days and 21.5 Hours
Abstract
The recently published study by Duan et al introduces a promising method that combines genomic instability and long non-coding RNAs to improve the prognostic evaluation of hepatocellular carcinoma (HCC), a deadly cancer associated with considerable morbidity and mortality. This editorial aims to analyze the methodology, key findings, and broader implications of the study within the fields of gastroenterology and oncological surgery, highlighting the shift towards precision medicine in the management of HCC.
Core Tip: The clinical approach used in hepatocellular carcinoma (HCC) is variable due to its heterogeneity and the unpredictable outcomes, and many patients unfortunately have a poor prognosis. Thus, the discovery of new biomarker candidates is necessary to aid in HCC clinical practice. In light of this, genomic instability (GI) derived HCC genetic biomarkers have not been fully explored as a novel prognostic signature, and may have a key role in this field. Therefore, the potential use of GI and long non-coding RNAs in refining risk stratification and guiding therapeutic decision-making has emerged.
